当前位置: 首页 >> 检索结果
共有 4132 条符合本次的查询结果, 用时 5.7785958 秒

1641. Health is global.

作者: Peter Piot.;Geoff Garnett.
来源: Lancet. 2009年374卷9696期1122-3页

1642. Canada 2010: what should global health expect?

作者: Richard Horton.
来源: Lancet. 2009年374卷9697期1215-6页

1643. Child undernutrition, tropical enteropathy, toilets, and handwashing.

作者: Jean H Humphrey.
来源: Lancet. 2009年374卷9694期1032-1035页

1644. Shall we put the world on folate?

作者: Anja Osterhues.;Wolfgang Holzgreve.;Karin B Michels.
来源: Lancet. 2009年374卷9694期959-961页

1645. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials.

作者: John J Aponte.;David Schellenberg.;Andrea Egan.;Alasdair Breckenridge.;Ilona Carneiro.;Julia Critchley.;Ina Danquah.;Alexander Dodoo.;Robin Kobbe.;Bertrand Lell.;Jürgen May.;Zul Premji.;Sergi Sanz.;Esperanza Sevene.;Rachida Soulaymani-Becheikh.;Peter Winstanley.;Samuel Adjei.;Sylvester Anemana.;Daniel Chandramohan.;Saadou Issifou.;Frank Mockenhaupt.;Seth Owusu-Agyei.;Brian Greenwood.;Martin P Grobusch.;Peter G Kremsner.;Eusebio Macete.;Hassan Mshinda.;Robert D Newman.;Laurence Slutsker.;Marcel Tanner.;Pedro Alonso.;Clara Menendez.
来源: Lancet. 2009年374卷9700期1533-42页
Intermittent preventive treatment (IPT) is a promising strategy for malaria control in infants. We undertook a pooled analysis of the safety and efficacy of IPT in infants (IPTi) with sulfadoxine-pyrimethamine in Africa.

1646. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates.

作者: James P Watt.;Lara J Wolfson.;Katherine L O'Brien.;Emily Henkle.;Maria Deloria-Knoll.;Natalie McCall.;Ellen Lee.;Orin S Levine.;Rana Hajjeh.;Kim Mulholland.;Thomas Cherian.; .
来源: Lancet. 2009年374卷9693期903-11页
Haemophilus influenzae type b (Hib) is a leading cause of childhood bacterial meningitis, pneumonia, and other serious infections. Hib disease can be almost completely eliminated through routine vaccination. We assessed the global burden of disease to help national policy makers and international donors set priorities.

1647. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates.

作者: Katherine L O'Brien.;Lara J Wolfson.;James P Watt.;Emily Henkle.;Maria Deloria-Knoll.;Natalie McCall.;Ellen Lee.;Kim Mulholland.;Orin S Levine.;Thomas Cherian.; .
来源: Lancet. 2009年374卷9693期893-902页
Streptococcus pneumoniae is a leading cause of bacterial pneumonia, meningitis, and sepsis in children worldwide. However, many countries lack national estimates of disease burden. Effective interventions are available, including pneumococcal conjugate vaccine and case management. To support local and global policy decisions on pneumococcal disease prevention and treatment, we estimated country-specific incidence of serious cases and deaths in children younger than 5 years.

1648. Consent for biobank tissue in somatic-cell nuclear transfer.

作者: David A Jones.;Calum MacKellar.
来源: Lancet. 2009年374卷9693期861-3页

1649. Mitral stenosis.

作者: Y Chandrashekhar.;Stephen Westaby.;Jagat Narula.
来源: Lancet. 2009年374卷9697期1271-83页
Mitral stenosis is a common disease that causes substantial morbidity worldwide. The disease is most prevalent in developing countries, but is increasingly being identified in an atypical form in developed countries. All treatments that increase valve area improve morbidity. Mortality improves with surgery; the benefit of percutaneous balloon valvuloplasty to mortality might be similar to that of surgery but needs further study. Percutaneous balloon valvuloplasty is the treatment of choice for patients in whom treatment is indicated, except for those with suboptimum valve morphology, and even these patients are sometimes treated with this procedure if surgery is not feasible or if surgical risk is prohibitive. We review the pathology, diagnosis, and treatment options for patients with mitral stenosis.

1650. Cleft lip and palate.

作者: Peter A Mossey.;Julian Little.;Ron G Munger.;Mike J Dixon.;William C Shaw.
来源: Lancet. 2009年374卷9703期1773-85页
Clefts of the lip and palate are generally divided into two groups, isolated cleft palate and cleft lip with or without cleft palate, representing a heterogeneous group of disorders affecting the lips and oral cavity. These defects arise in about 1.7 per 1000 liveborn babies, with ethnic and geographic variation. Effects on speech, hearing, appearance, and psychology can lead to longlasting adverse outcomes for health and social integration. Typically, children with these disorders need multidisciplinary care from birth to adulthood and have higher morbidity and mortality throughout life than do unaffected individuals. This Seminar describes embryological developmental processes, epidemiology, known environmental and genetic risk factors, and their interaction. Although access to care has increased in recent years, especially in developing countries, quality of care still varies substantially. Prevention is the ultimate objective for clefts of the lip and palate, and a prerequisite of this aim is to elucidate causes of the disorders. Technological advances and international collaborations have yielded some successes.

1651. Rethinking the responsiveness requirement for international research.

作者: Rebecca Wolitz.;Ezekiel Emanuel.;Seema Shah.
来源: Lancet. 2009年374卷9692期847-9页

1652. Fad diets in Sweden, of all places.

作者: Jim Mann.;Edwin R Nye.
来源: Lancet. 2009年374卷9692期767-9页

1653. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.

作者: Michelle L O'Donoghue.;Eugene Braunwald.;Elliott M Antman.;Sabina A Murphy.;Eric R Bates.;Yoseph Rozenman.;Alan D Michelson.;Raymond W Hautvast.;Peter N Ver Lee.;Sandra L Close.;Lei Shen.;Jessica L Mega.;Marc S Sabatine.;Stephen D Wiviott.
来源: Lancet. 2009年374卷9694期989-997页
Proton-pump inhibitors (PPIs) are often prescribed in combination with thienopyridines. Conflicting data exist as to whether PPIs diminish the efficacy of clopidogrel. We assessed the association between PPI use, measures of platelet function, and clinical outcomes for patients treated with clopidogrel or prasugrel.

1654. New drugs for exacerbations of chronic obstructive pulmonary disease.

作者: Trevor T Hansel.;Peter J Barnes.
来源: Lancet. 2009年374卷9691期744-55页
Tobacco smoking is the dominant risk factor for chronic obstructive pulmonary disease (COPD), but viral and bacterial infections are the major causes of exacerbations in later stages of disease. Reactive oxygen species (ROS), pathogen-associated molecular patterns (PAMPs), and damage-associated molecular patterns (DAMPs) activate families of pattern recognition receptors (PRRs) that include the toll-like receptors (TLRs). This understanding has led to the hypothesis that COPD is an archetypal disease of innate immunity. COPD is characterised by abnormal response to injury, with altered barrier function of the respiratory tract, an acute phase reaction, and excessive activation of macrophages, neutrophils, and fibroblasts in the lung. The activated non-specific immune system then mediates the processes of inflammation and repair, fibrosis, and proteolysis. COPD is also associated with corticosteroid resistance, abnormal macrophage and T-cell populations in the airway, autoinflammation and autoimmunity, aberrant fibrosis, accelerated ageing, systemic and concomitant disease, and defective regeneration. Such concepts have been used to generate a range of molecular targets, and clinical trials are taking place to identify effective drugs for the prevention and treatment of COPD exacerbations.

1655. Chronic obstructive pulmonary disease in non-smokers.

作者: Sundeep S Salvi.;Peter J Barnes.
来源: Lancet. 2009年374卷9691期733-43页
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Tobacco smoking is established as a major risk factor, but emerging evidence suggests that other risk factors are important, especially in developing countries. An estimated 25-45% of patients with COPD have never smoked; the burden of non-smoking COPD is therefore much higher than previously believed. About 3 billion people, half the worldwide population, are exposed to smoke from biomass fuel compared with 1.01 billion people who smoke tobacco, which suggests that exposure to biomass smoke might be the biggest risk factor for COPD globally. We review the evidence for the association of COPD with biomass fuel, occupational exposure to dusts and gases, history of pulmonary tuberculosis, chronic asthma, respiratory-tract infections during childhood, outdoor air pollution, and poor socioeconomic status.

1656. Screening for and early detection of chronic obstructive pulmonary disease.

作者: Joan B Soriano.;Jan Zielinski.;David Price.
来源: Lancet. 2009年374卷9691期721-32页
Chronic obstructive pulmonary disease (COPD) is a substantially underdiagnosed disorder, with the diagnosis typically missed or delayed until the condition is advanced. Spirometry is the most frequently used pulmonary function test and enables health professionals to make an objective measurement of airflow obstruction and assess the degree to which it is reversible. As a diagnostic test for COPD, spirometry is a reliable, simple, non-invasive, safe, and non-expensive procedure. Early diagnosis of COPD should provide support for smoking cessation initiatives and lead to reduction of the societal burden of the disease, but definitive confirmation of both proves elusive. Despite substantial effort and investment, implementation of quality spirometry is deficient because of several hurdles and limitations, described in this Review. All in all, spirometry is recognised as the essential test for diagnosis and monitoring of COPD.

1657. Elective caesarean sections--risks to the infant.

作者: Philip J Steer.;Neena Modi.
来源: Lancet. 2009年374卷9691期675-6页

1658. Telemedicine for management of patients with COPD?

作者: Brian McKinstry.;Hilary Pinnock.;Aziz Sheikh.
来源: Lancet. 2009年374卷9691期672-3页

1659. Time to define the disorders of the syndrome of COPD.

作者: Richard Beasley.;Mark Weatherall.;Justin Travers.;Philippa Shirtcliffe.
来源: Lancet. 2009年374卷9691期670-2页

1660. Achieving the health Millennium Development Goals for South Africa: challenges and priorities.

作者: Mickey Chopra.;Joy E Lawn.;David Sanders.;Peter Barron.;Salim S Abdool Karim.;Debbie Bradshaw.;Rachel Jewkes.;Quarraisha Abdool Karim.;Alan J Flisher.;Bongani M Mayosi.;Stephen M Tollman.;Gavin J Churchyard.;Hoosen Coovadia.; .
来源: Lancet. 2009年374卷9694期1023-1031页
15 years after liberation from apartheid, South Africans are facing new challenges for which the highest calibre of leadership, vision, and commitment is needed. The effect of the unprecedented HIV/AIDS epidemic has been immense. Substantial increases in mortality and morbidity are threatening to overwhelm the health system and undermine the potential of South Africa to attain the Millennium Development Goals (MDGs). However The Lancet's Series on South Africa has identified several examples of leadership and innovation that point towards a different future scenario. We discuss the type of vision, leadership, and priority actions needed to achieve such a change. We still have time to change the health trajectory of the country, and even meet the MDGs. The South African Government, installed in April, 2009, has the mandate and potential to address the public health emergencies facing the country--will they do so or will another opportunity and many more lives be lost?
共有 4132 条符合本次的查询结果, 用时 5.7785958 秒